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Background: There are limited data on gender differences among patients presenting with acute decompensated heart failure (ADHF) outside the 
North American and European regions.
Methods: The ADHERE-International registry consists of 9702 ADHF admissions from 70 hospitals in the Asia Pacific and Latin America regions from 
2005-9. We compared the characteristics, quality of care (QOC) measures, and in-hospital outcomes between genders. The impact of gender was 
assessed with multivariable regression model, using generalized estimating equations to account for within hospital clustering.
Results: Females accounted for 42% of the cohort. Baseline characteristics differ between genders (Table). Females were less likely to be 
prescribed angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), beta-blocker, and diuretics both on admission and 
upon discharge. After adjusting for patients’ characteristics, there were no differences between gender for in-hospital outcomes and QOC measures, 
except a modest association of male gender with the use of ACEi or ARB in patients with systolic impairment (Adjusted OR 1.14; 95% CI 1.00-1.29, 
P=0.048).
Conclusions: There are gender differences in patient characteristics, therapies, and QOC measures among ADHF admissions in Asian Pacific and 
Latin American countries, which are largely accounted for based on differences in age and baseline characteristics and were not associated with 
gender differences for in-hospital outcomes. 
Table: Patients Baseline Characteristics, In-hospital Management, Quality of Care Measures and In-hospital Outcomes Stratified by Gender 
(Unadjusted).
Female Male Total P Value*
BASELINE CHARACTERISTICS
Age (years) 67.8±15.3 63.7±14.5 65.4±14.9 <0.0001
Medical History
Ischemic Heart Disease 41.8 54.5 49.2 <0.0001
Hypertension 69.5 61.8 65.0 <0.0001
Atrial Fibrillation 25.9 23.1 24.3 0.0015
Diabetes Mellitus 46.9 43.6 45.0 0.0011
Renal Insufficiency (Serum Cr >2.0) 20.9 23.7 22.5 0.0010
Baseline Findings
Initial Systolic Blood Pressure (mmHg) 141.9±33.0 132.5±30.8 136.5±32.1 <0.0001
LVEF ≥40% 49.5 29.5 37.9 <0.0001
QUALITY OF CARE MEASURES
All patients
LVEF Evaluation 83.6 86.9 85.5 <0.0001
Discharge Instruction Documentation 92.7 93.5 93.2 0.1705
Smoking Cessation Advice 14.5 25.0 23.9 0.0064
Warfarin for AF 37.9 40.9 39.5 0.1085
Patients with LV Systolic Dysfunction
ACEi/ARB use 72.2 75.2 74.3 0.0447
Beta-blocker use 47.4 50.6 49.6 0.0612
Aldosterone antagonists 38.9 45.2 43.3 0.0002
IN-HOSPITAL OUTCOMES
In-hospital mortality 4.2 4.8 4.5 0.1500
Median Hospital LOS (Days) 6 (3, 10) 6 (3, 10) 6 (3, 10) 0.1214
* P-values calculated for between gender comparisons. Wilcoxon two-sample test performed for continuous variables, Chi-square test for categorical 
variables. For categorical variables, values reported as percentage (%). For continuous variables, values reported as mean±S.D. or median (25th, 
95th percentiles).
ACEi= Angiotensin converting enzyme inhibitors; ARB= Angiotensin receptor blockers; LVEF= left ventricular ejection fraction; LOS= length of stay
